Caffeine can interfere with the work of antidepressants

New research has shown an unexpected link between caffeine and the most effective modern treatments for depression. As it turned out, the substance adenosine, which plays a key role in the action of ketamine and electroconvulsive therapy (ECT), is blocked by caffeine, the main active component of coffee, tea and energy drinks.

Caffeine can interfere with the work of antidepressants

The main reason is a substance called adenosine. It is a molecule that helps the brain to calm down and recover. Studies have shown that it is adenosine that triggers the process of improving mood and reduces symptoms of depression under the influence of ketamine and ECT. If you block it, the effect of the treatment disappears.

And caffeine, the main component of coffee, tea, and energy drinks, blocks adenosine receptors. Because of this, coffee can interfere with medications. “Patients often come to procedures after drinking their morning coffee, and do not even suspect that it can reduce the effectiveness of therapy,” the authors of the study note.

Interestingly, in the long run, caffeine, on the contrary, can be useful. Regular moderate coffee consumption is associated with a lower risk of depression. Scientists suggest that caffeine helps maintain a stable mood, but during active treatment it can interfere with brain function and weaken the therapeutic effect.

In addition, the researchers found that the antidepressant effect occurs not only when taking ketamine or ECT. Therapy with short—term hypoxia, a controlled decrease in oxygen levels, works in a similar way. This method also activates adenosine, but it is safer and may be suitable for mass use.

Now experts want to find out exactly how coffee affects different treatments for depression and whether it is worth temporarily giving up caffeine before therapy sessions.

Published

November, 2025

Category

Medicine

Duration of reading

1–2 minutes

Share

Don’t miss the most important science and health updates!

Subscribe to our newsletter and get the most important news straight to your inbox

Send us a message